Literature DB >> 8513578

Adjuvant treatment increases the resistance to Mycobacterium avium infection of mycobacteria-susceptible BALB/c mice.

A P Castro1, A P Aguas, M T Silva.   

Abstract

We have investigated the effect of inflammation on host resistance against infection by Mycobacterium avium, an atypical mycobacteria species that is responsible for life-threatening opportunistic infections in AIDS patients. Inflammation was induced in BALB/c mice by two intraperitoneal injections of mineral oil (Freund's incomplete adjuvant, FIA). The BALB/c strain was chosen because it is naturally susceptible to Myco. avium infection. One week after the second FIA injection, the BALB/c mice were infected intravenously with 2.6 x 10(6) Myco. avium bacilli; at this time, the mice showed systemic granulocytosis because of the FIA injections. The kinetics of the murine infection was determined during 3 months by quantification of Myco. avium loads in the major target organs (liver and spleen) of the mycobacteria. The FIA treatment resulted in a significant decrease in the growth of Myco. avium in the infected BALB/c mice. This enhancement in host resistance to Myco. avium infection lasted for 2-3 months. In contrast with BALB/c animals, C3H mice (naturally resistant to Myco. avium infection) did not show an increased anti-Myco. avium action in association with the FIA treatment. The antimycobacterial effect of the FIA injections in BALB/c mice was compared with that produced by the injection of mycobacterial antigens (heat-killed Myco. tuberculosis) added to the mineral oil (i.e. Freund's complete adjuvant, FCA). The FCA treatment resulted in strong and sustained enhancements in the microbicidal capacities of BALB/c, and also of C3H mice. Data obtained with mutant athymic BALB/c mice revealed that the anti-Myco. avium effect of the FCA treatment was T cell-dependent. Our results indicate that: (i) non-immune inflammatory stimulation (FIA) of Myco. avium-susceptible hosts is able to cause a significant, albeit transient, increase in the resistance to Myco. avium infection; (ii) this protective effect is enhanced if heat-killed mycobacteria are added to the phlogistic agent (FCA), i.e. if a T cell-dependent response is induced; and (iii) systemic increase in the number of circulating granulocytes may help host defence against Myco. avium infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513578      PMCID: PMC1554779          DOI: 10.1111/j.1365-2249.1993.tb03422.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  The mode of action of mineral-oil emulsion adjuvants on antibody production in mice.

Authors:  W J Herbert
Journal:  Immunology       Date:  1968-03       Impact factor: 7.397

2.  Effects of oil-treated mycobacterial cell walls on the organs of mice.

Authors:  W R Barclay; R Anacker; W Brehmer; E Ribi
Journal:  J Bacteriol       Date:  1967-11       Impact factor: 3.490

3.  Biologically active components from mycobacterial cell walls. V. Granuloma formation in mouse lungs and guinea pig skin.

Authors:  T J Meyer; E Ribi; I Azuma
Journal:  Cell Immunol       Date:  1975-03       Impact factor: 4.868

4.  Genetic regulation of resistance to intracellular pathogens.

Authors:  E Skamene; P Gros; A Forget; P A Kongshavn; C St Charles; B A Taylor
Journal:  Nature       Date:  1982-06-10       Impact factor: 49.962

5.  [Inflammation and resistance of mice against "Plasmodium berghei" (author's transl)].

Authors:  J C Michel; B Hurtrel; P H Lagrange
Journal:  Ann Immunol (Paris)       Date:  1982 Jan-Feb

6.  Effective nonliving vaccine against experimental tuberculosis in mice.

Authors:  E Ribi; C Larson; W Wicht; R List; G Goode
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

7.  Clinical and epidemiological importance of typing of Mycobacterium avium complex isolates.

Authors:  A Y Tsang; J C Denner; P J Brennan; J K McClatchy
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

8.  The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin.

Authors:  R Bomford
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

9.  Effectiveness of cell walls of Mycobacterium bovis strain BCG administered by various routes and in different adjuvants in protecting mice against airborne infection with Mycobacterium tuberculosis strain H37Rv.

Authors:  R L Anacker; W R Barclay; W Brehmer; G Goode; R H List; E Ribi; D F Tarmina
Journal:  Am Rev Respir Dis       Date:  1969-02

10.  Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients.

Authors:  I M Orme; F M Collins
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

View more
  3 in total

1.  Stress modulates acute inflammation triggered by mycobacteria in autoimmunity-prone and normal mice.

Authors:  T C Martins; A P Aguas
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

2.  In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine.

Authors:  Divya Sagar; Shet Masih; Todd Schell; Steven Jacobson; Joseph D Comber; Ramila Philip; Brian Wigdahl; Pooja Jain; Zafar K Khan
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

3.  Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund's adjuvant, and monophosphoryl lipid A.

Authors:  Juliana Vitoriano-Souza; Nádia das Dores Moreira; Andréa Teixeira-Carvalho; Cláudia Martins Carneiro; Fernando Augusto Mathias Siqueira; Paula Melo de Abreu Vieira; Rodolfo Cordeiro Giunchetti; Sandra Aparecida de Lima Moura; Ricardo Toshio Fujiwara; Maria Norma Melo; Alexandre Barbosa Reis
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.